Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Locally advanced (Stage IIIB), metastatic (Stage IV) or recurrent non-small cell lung
cancer with mutations in the tyrosine kinase domain of the epidermal growth factor
receptor (EGFR)

- At least one measurable lesion according to RECIST criteria

- European Cooperative Oncology Group (ECOG) performance status 0-2

- Adequate hematological, liver and renal function

- Patients with stable cerebral metastases who have received surgical or radiotherapy
will be eligible

Exclusion Criteria:

- Previous chemotherapy or therapy against EGFR for metastatic disease (neoadjuvant or
adjuvant therapy after radical surgery is allowed if finalized >/= 6 months before
entering the study)

- History of another neoplasm except for carcinoma in situ of the cervix, adequately
treated basal cell skin carcinoma, radically treated prostate carcinoma with good
prognosis (Gleason disease in the last 5 years

- Symptomatic cerebral metastases

- Any significant ophthalmologic abnormality

- Use of coumarins

- Pregnant or breast-feeding women

- Pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis and
carcinomatosis (if this is the only presence of the disease)